ArticleJournal of psychopharmacology (Oxford, England)2021
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.
Article in Journal of psychopharmacology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Keeping the promise: a critique of the current state of microdosing research.Frontiers in psychiatry · 2024Pooled it
- Therapeutic effect of psilocybin in addiction: A systematic review.Frontiers in psychiatry · 2023Pooled it
- Pharmacokinetics of N,N-dimethyltryptamine in Humans.European journal of drug metabolism and pharmacokinetics · 2023Trial
- Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.Translational psychiatry · 2022Trial
- Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.Clinical pharmacology and therapeutics · 2022Trial
- Psychedelics align brain activity with context.Nature · 2026Article
- Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.medRxiv : the preprint server for health sciences · 2026Article
- Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling.bioRxiv : the preprint server for biology · 2026Article
- Psilocibin: Current Evidence, Safety Signals, and Challenges in Assessing Potential Multi-Organ Effects.Biomedicines · 2026Review
- Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review.Psychedelic medicine (New Rochelle, N.Y.) · 2026Review
- Pilot study of psilocybin in patients with post-treatment lyme disease.Scientific reports · 2026Article
- Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics.Journal of psychopharmacology (Oxford, England) · 2026Review
- Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.BJPsych open · 2025Article
- Psychedelic interventions for major depressive disorder in the elderly: Exploring novel therapies, promise and potential.Dialogues in clinical neuroscience · 2025Review
- Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice.Psychopharmacology · 2025Article
- The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting.Pharmacological reports : PR · 2025Article
- Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology · 2025Review
- Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.Psychopharmacology · 2025Article
- Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.Journal of racial and ethnic health disparities · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGrowing evidence suggests psilocybin, a naturally occurring psychedelic, is a safe and promising pharmacotherapy for treatment of mood and substance use disorders when administered as part of a structured intervention. In most trials to date, psilocybin dose has been administered on a weight-adjusted basis rather than the more convenient procedure of administering a fixed dose.
aimsThe present post hoc analyses sought to determine whether the subjective effects of psilocybin are affected by body weight when psilocybin is administered on a weight-adjusted basis and when psilocybin is administered as a fixed dose.
methodsWe analyzed acute subjective drug effects (mystical, challenging, and intensity) associated with therapeutic outcomes from ten previous studies (total
resultsIn the 20 mg/70 kg and 30 mg/70 kg weight-adjusted groups, and in the fixed dose group, no significant associations were found between subjective effects and demographic variables including body weight or sex. Across a wide range of body weights (49 to 113 kg) the present results showed no evidence that body weight affected subjective effects of psilocybin.
conclusionsThese results suggest that the convenience and lower cost of administering psilocybin as a fixed dose outweigh any potential advantage of weight-adjusted dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.